# Role of interleukin-6-mediated inflammation in the pathogenesis of inflammatory bowel disease

is not limited to reducing IL-6 and can affect other inflammatory mediators and improve the mucosal barrier.

# Acknowledgements

Mashhad University of Medical Sciences supported this study.

# Declarations

# Conflict of interest

None.

# References

1. Ahluwalia B, Moraes L, Magnusson MK, Öhman L (2018) Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. Scand J Gastroenterol 53(4):379–389
2. Ananthakrishnan AN (2015) Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol 12(4):205–217
3. Asensi V, Valle E, Meana A, Fierer J, Celada A, Alvarez V, Paz J, Coto E, Carton JA, Maradona JA (2004) In vivo interleukin-6 protects neutrophils from apoptosis in osteomyelitis. Infect Immun 72(7):3823–3828
4. Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, Schütz M, Bartsch B, Holtmann M, Becker C (2000) Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 6(5):583–588
5. Atreya R, Neurath M (2008) New therapeutic strategies for treatment of inflammatory bowel disease. Mucosal Immunol 1(3):175–182
6. Barnes TC, Anderson ME, Moots RJ (2011) The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. Int J Rheumatol. https://doi.org/10.1155/2011/721608
7. Becker C, Dornhoff H, Neufert C, Fantini MC, Wirtz S, Huebner S, Nikolaev A, Lehr H-A, Murphy AJ, Valenzuela DM (2006) Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J Immunol 177(5):2760–2764
8. Beltrán CJ, Núñez LE, Díaz-Jiménez D, Farfan N, Candia E, Heine C, López F, González MJ, Quera R, Hermoso MA (2010) Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis 16(7):1097–1107
9. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441(7090):235–238
10. Boe A, Baiocchi M, Carbonatto M, Papoian R, Serlupi-Crescenzi O (1999) Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis. Cytokine 11(12):1057–1064
11. Borghini R, Vescovo M, Giordano C, Donato G, Picarelli A (2021) Onset of suspected ulcerative colitis after treatment with tocilizumab in patient with celiac disease and juvenile idiopathic arthritis. Inflamm Bowel Dis 27(6):e76–e78
12. Bouguen G, Chevaux J-B, Peyrin-Biroulet L (2011) Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases. World J Gastroenterol: WJG 17(5):547
13. Bradham C, McClay DR (2006) p38 MAPK in development and cancer. Cell Cycle 5(8):824–828
14. Bray SJ (2006) Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol 7(9):678–689
15. Brzozowski B, Mazur-Bialy A, Pajdo R, Kwiecien S, Bilski J, Zwolinska-Wcislo M, Mach T, Brzozowski T (2016) Mechanisms by which stress affects the experimental and clinical inflammatory bowel disease (IBD): role of brain-gut axis. Curr Neuropharmacol 14(8):892–900
16. Buonocore S, Ahern PP, Uhlig HH, Ivanov II, Littman DR, Maloy KJ, Powrie F (2010) Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 464(7293):1371–1375
17. Cai J, Zhang N, Zheng Y, De Wilde RF, Maitra A, Pan D (2010) The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev 24(21):2383–2388
18. Caiello I, Minnone G, Holzinger D, Vogl T, Prencipe G, Manzo A, De Benedetti F, Strippoli R (2014) IL-6 amplifies TLR mediated cytokine and chemokine production: implications for the pathogenesis of rheumatic inflammatory diseases. PLoS ONE 9(10):e107886
19. Calabrese LH, Rose-John S (2014) IL-6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol 10(12):720–727
20. Cao J, Zhang H, Yang Z, Zhao J, Ma H (2020) Effect of dehydroepiandrosterone on the immune response and gut microbiota in dextran sulfate sodium-induced colitis mice. Mol Immunol 118:60–72
21. Cao Q, Lin Y, Yue C, Wang Y, Quan F, Cui X, Bi R, Tang X, Yang Y, Wang C (2021) IL-6 deficiency promotes colitis by recruiting Ly6Chi monocytes into inflamed colon tissues in a CCL2-CCR2-dependent manner. Eur J Pharmacol 904:174165
22. Chen W, Yuan H, Cao W, Wang T, Chen W, Yu H, Fu Y, Jiang B, Zhou H, Guo H (2019) Blocking interleukin-6 trans-signaling protects against renal fibrosis by suppressing STAT3 activation. Theranostics 9(14):3980
23. Chen Y, Chen H, Ding J, Stanton C, Ross RP, Zhao J, Zhang H, Yang B, Chen W (2021) Bifidobacterium longum ameliorates dextran sulfate sodium-induced colitis by producing conjugated linoleic acid, protecting intestinal mechanical barrier, restoring unbalanced gut Microbiota, and regulating the toll-like receptor-4/Nuclear Factor-κB signaling pathway. J Agric Food Chem 69(48):14593–14608
24. Choi JS, Kim K-H, Lau LF (2015) The matricellular protein CCN1 promotes mucosal healing in murine colitis through IL-6. Mucosal Immunol 8(6):1285–1296
25. Chonov DC, Ignatova MMK, Ananiev JR, Gulubova MV (2019) IL-6 activities in the tumour microenvironment. Part 1. Open Access Macedonian J Med Sci 7(14):2391
26. Clarke WT, Feuerstein JD (2019) Colorectal cancer surveillance in inflammatory bowel disease: practice guidelines and recent developments. World J Gastroenterol 25(30):4148
27. Coskun M, Vermeire S, Nielsen OH (2017) Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol Sci 38(2):127–142
28. Dai Y, Jiao H, Teng G, Wang W, Zhang R, Wang Y, Hebbard L, George J, Qiao L (2014) Embelin reduces colitis-associated tumorigenesis through limiting IL-6/STAT3 signaling. Mol Cancer Ther 13(5):1206–1216
29. Danese S, Vermeire S, Hellstern P, Panaccione R, Rogler G, Fraser G, Kohn A, Desreumaux P, Leong RW, Comer GM (2019) Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II). Gut 68(1):40–48
30. De Souza HS, Fiocchi C (2016) Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol 13(1):13–27
31. Deiana M, Serra G, Corona G (2018) Modulation of intestinal epithelium homeostasis by extra virgin olive oil phenolic compounds. Food Funct 9(8):4085–4099
32. Deng J, Zhao L, Yuan X, Li Y, Shi J, Zhang H, Zhao Y, Han L, Wang H, Yan Y (2022) Pre-administration of berberine exerts chemopreventive effects in aom/dss-induced colitis-associated carcinogenesis mice via modulating inflammation and intestinal microbiota. Nutrients 14(4):726